IP Library Granted Patent US 9,322,800
Granted Patent B2
US 9,322,800 · App. 13/261,834 · Granted Apr 26, 2016

Hematocrit corrected glucose measurements using phase angles and impedance for electrochemical test strip

Inventors: David McColl (Inverness, GB); Mandip Farmahan (Inverness, GB); Antony Smith (Inverness, GB)
Assignee: LifeScan Scotland Limited
G01N27/416G01N27/3274
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,322,800
App. No.
13/261,834
Granted
Apr 26, 2016
Kind
B2
Abstract

Two techniques of determining hematocrit using impedance and phase angle to determine hematocrit are shown and described for correcting an analyte concentration.

Claims (115)

1. A method to determine analyte concentration in a blood sample, the method comprising:

depositing a blood sample in a test chamber of a test strip having at least first and second electrodes in contact with a reagent and third and fourth electrodes not in contact with the reagent;

driving a non-oscillating signal to the at least first and second electrodes to cause a reaction with the glucose in the blood sample and the reagent;

measuring a current output of the reaction to establish a preliminary analyte concentration;

applying a first oscillating input signal at a first frequency to third and fourth electrodes, the first frequency comprising any frequency in a range of about 20,000 Hertz to about 60,000 Hertz;

determining a first estimated hematocrit based on an impedance from output signals of the third and fourth electrodes;

applying a second oscillating input signal at a second frequency higher than the first frequency to the third and fourth electrodes, the second frequency comprising any frequency in a range from about 100,000 Hertz to about 1,000,000 Hertz;

ascertaining a second estimated hematocrit based on a phase angle of output signals from the third and fourth electrodes;

estimating a hematocrit of the blood sample based on the first and second estimated hematocrits; and

deriving a final analyte concentration based on the preliminary analyte concentration and the hematocrit from the estimating step.

2. The method of claim 1 , in which the second frequency is one order of magnitude higher than the first frequency.

3. The method of claim 2 , in which the first frequency comprises about 25,000 Hertz and the second frequency comprises about 250,000 Hertz.

4. The method of claim 1 , in which the determining comprises utilizing an equation to determine the first estimated hematocrit HCT est1 :

HCT

est

1

=

Z

-

c

1

m

1

where |Z| comprises the measured modulus of impedance of the blood sample at the first frequency, c1 and m1 are calibration coefficients.

5. The method of claim 4 , in which the measuring of a current output for the preliminary analyte concentration is performed prior to the estimating of the hematocrit.

6. The method of claim 4 , in which the deriving comprises calculating the final analyte concentration G F from:

G

F

=

(

I

E

1

-

k

(

HCT

final_est

-

h

0

)

-

c

4

m

4

.

Where

I E comprises a magnitude of the measured end current

HCT final _ est comprises the hematocrit,

h 0 comprises nominal hematocrit,

and k, m4 and c 4 comprise parameters from regressions data.

7. The method of claim 1 , in which the ascertaining comprises utilizing an equation to determine the second estimated hematocrit HCT est2 of the form:

HCT

est

2

=

(

Φ

-

c

2

)

m

2

where Φ comprises a measured phase angle of the blood sample at one or more second frequencies higher than the first frequency; c2 and m2 comprise respective calibration coefficients.

8. The method of claim 1 , in which the ascertaining comprises utilizing an equation to determine the second estimated hematocrit HCT est2 of the form:

HCT

est

2

=

(

Φ

f

2

-

Φ

f

1

-

c

3

)

m

3

where Φ f2 comprises a measured phase angle of the blood sample at the second frequency; Φ f1 comprises a measured phase angle of the blood sample at the first frequency lower than the second frequency; c3 and m3 each comprises a calibration coefficient.

9. The method of claim 1 , in which the estimating comprises utilizing an equation for a final estimated hematocrit HCT final _ est of the form:

HCT final _ est =a *HCT est1 +( a− 1)*HCT est2

where HCT est1 comprises the first estimated hematocrit and HCT est2 comprises a second estimated hematocrit and a≦1.

10. The method of claim 1 , in which the analyte comprises glucose.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2026
From: LIFESCAN GLOBAL CORPORATION; LIFESCAN CHINA, LLC; LIFESCAN IP HOLDINGS, LLC
To: LIFESCAN ENTERPRISES LLC
Reel/Frame 075848/0012 →
RELEASE OF SECURITY INTEREST Recorded Dec 8, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSBWILMINGTON SAVINGS FUND SOCIETY, FSB
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 073928/0626 →
RELEASE OF SECURITY INTEREST Recorded Dec 8, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 073929/0316 →
RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED OCT. 3, 2018, REEL/FRAME 047186/0836 Recorded Jun 28, 2023
From: BANK OF AMERICA, N.A.
To: LIFESCAN IP HOLDINGS, LLC; JANSSEN BIOTECH, INC.; JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 064206/0176 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded May 23, 2023
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 063740/0080 →
FIRST LIEN PATENT SECURITY AGREEMENT Recorded May 22, 2023
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 063712/0430 →
CORRECTIVE ASSIGNMENT TO CORRECT THE DELETING PROPERTY NUMBER 6990849, 7169116, 7351770, 7462265,7468125, 7572356, 8093903, 8486245, 8066866 AND ADD 10431140 PREVIOUSLY RECORDED AT REEL: 050839 FRAME: 0634. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 12, 2023
From: LIFESCAN SCOTLAND LTD.
To: CILAG GMBH INTERNATIONAL
Reel/Frame 064656/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: CILAG GMBH INTERNATIONAL
To: LIFESCAN IP HOLDINGS, LLC
Reel/Frame 050840/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2019
From: LIFESCAN SCOTLAND LTD.
To: CILAG GMBH INTERNATIONAL
Reel/Frame 050839/0634 →
SECURITY AGREEMENT Recorded Oct 3, 2018
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047186/0836 →
SECURITY AGREEMENT Recorded Oct 2, 2018
From: LIFESCAN IP HOLDINGS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 047179/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2016
From: MCCOLL, DAVID; FARMAHAN, MANDIP; SMITH, ANTONY
To: LIFESCAN SCOTLAND LIMITED
Reel/Frame 038048/0619 →
Continuity (2)
Provisional Application 61530808 · Sep 2, 2011
Related Publication 20140231273A1 · Aug 21, 2014